Manufacturers of brand-name biologic drugs are likely to be the same ones making less-expensive biosimilar drugs, at least initially, outgoing Actavis CEO Claudio Albrecht said. After the FDA establishes a regulatory path for biosimilars, large generic-drug-makers such as Teva Pharmaceutical Industries, Mylan and Watson will dominate the market, Albrecht predicted.

Full Story:

Related Summaries